Unity Biotechnology, Inc.UBXNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank31
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P31
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q1 2025 | -3.11% |
| Q4 2024 | 11.43% |
| Q3 2024 | 8.50% |
| Q2 2024 | -13.21% |
| Q1 2024 | -7.41% |
| Q4 2023 | -1.20% |
| Q3 2023 | -18.50% |
| Q2 2023 | 12.76% |
| Q1 2023 | -8.75% |
| Q4 2022 | 7.27% |
| Q3 2022 | -0.38% |
| Q2 2022 | -14.90% |
| Q1 2022 | 13.78% |
| Q4 2021 | -11.21% |
| Q3 2021 | -3.90% |
| Q2 2021 | -3.95% |
| Q1 2021 | 19.23% |
| Q4 2020 | -20.03% |
| Q3 2020 | 3.32% |
| Q2 2020 | 6.16% |
| Q1 2020 | 21.32% |
| Q4 2019 | -13.79% |
| Q3 2019 | 14.53% |
| Q2 2019 | 11.01% |
| Q1 2019 | 3.44% |
| Q4 2018 | -1.39% |
| Q3 2018 | 14.24% |
| Q2 2018 | 11.14% |
| Q1 2018 | 34.15% |
| Q4 2017 | 3.74% |
| Q3 2017 | -0.04% |
| Q2 2017 | 20.05% |
| Q1 2017 | 0.00% |